ChiCTR2100047946 版本V1.0 版本创建时间2021/07/06 19:12:48 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100047946 

最近更新日期:

Date of Last Refreshed on:

2021-06-28 03:53:20 

注册时间:

Date of Registration:

2021-06-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件。 水疗与经颅直流电刺激结合对儿童脑瘫的疗效观察

Public title:

Combined effect of hydrotherapy and Transcranial Direct-Current Stimulation on children with cerebral palsy.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

水疗与经颅直流电刺激结合对儿童脑瘫的疗效观察

Scientific title:

Combined effect of hydrotherapy and Transcranial Direct-Current Stimulation on children with cerebral palsy.

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈晓亮 

研究负责人:

陈晓亮 

Applicant:

Xiao-Liang Chen 

Study leader:

Xiao-Liang Chen 

申请注册联系人电话:

Applicant telephone:

13919088491

研究负责人电话:

Study leader's telephone:

13919088491

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2010662788@qq.com

研究负责人电子邮件:

Study leader's E-mail:

2010662788@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

黑龙江省齐齐哈尔市龙沙区中华西路37号

研究负责人通讯地址:

黑龙江省齐齐哈尔市龙沙区中华西路37号

Applicant address:

No.37, Zhonghua West Road, Longsha District, Qiqihar City, Heilongjiang Province

Study leader's address:

No.37, Zhonghua West Road, Longsha District, Qiqihar City, Heilongjiang Province

申请注册联系人邮政编码:

Applicant postcode:

161041

研究负责人邮政编码:

Study leader's postcode:

161041

申请人所在单位:

齐齐哈尔医学院附属第二医院

Applicant's institution:

the Second Affiliated Hospital of Qiqihar Medical University

研究负责人所在单位:

齐齐哈尔医学院附属第二医院

Affiliation of the Leader:

the Second Affiliated Hospital of Qiqihar Medical University

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

齐齐哈尔医学院附属第二医院

Primary sponsor:

the Second Affiliated Hospital of Qiqihar Medical University

研究实施负责(组长)单位地址:

黑龙江省齐齐哈尔市龙沙区中华西路37号

Primary sponsor's address:

No.37, Zhonghua West Road, Longsha District, Qiqihar City, Heilongjiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

黑龙江

市(区县):

齐齐哈尔

Country:

China

Province:

Heilongjiang

City:

Qiqihar

单位(医院):

齐齐哈尔医学院附属第二医院

具体地址:

龙沙区中华西路37号

Institution
hospital:

the Second Affiliated Hospital of Qiqihar Medical University

Address:

37 Zhonghua Road West, Longsha District

经费或物资来源:

自费

Source(s) of funding:

none

Target disease:

cerebral palsy

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评估经颅直流电刺激和水疗联合应用对儿童脑瘫的疗效。  

Objectives of Study:

To estimate the efficacy of a combined application of tDCS and hydrotherapy in patients with CP, compared to treatment as usual.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1) 4-14 岁脑瘫患者, (2) 根据中华医学会康复专科组诊断标准诊断为脑瘫患者, (3) 自愿参加并签署知情同意书。

Inclusion criteria

(1) cerebral palsy patients between 4 and 14 years old, (2) cerebral palsy was diagnosed according to the diagnostic criteria of CP found in the Subspecialty Group of Rehabilitation of Chinese Medical Association, (3) voluntary participation and informed consent signed.

排除标准:

(1)影响评价结果的视觉、听觉、精神障碍; (2) 药物治疗无法控制的癫痫患儿; (3) 开放性伤口或活动性感染等皮肤问题; (4) 项目开始前6个月内接受过肉毒杆菌毒素注射或手术; (5) 参加另一项临床试验; (6)意识不清,行为异常或无法控制,在治疗过程中易发生医疗事故d的患者。

Exclusion criteria:

(1) visual, auditory, and mental disorders affecting the results assessment; (2) children with epilepsy who are uncontrolled with medication; (3) skin problems such as open wounds or active infection; (4) receiving botulinum toxin injections or surgery no earlier than 6 months before project start; (5) participation in another clinical trial; (6) unconscious, behaving strangely or uncontrollably, and are prone to medical accidents during treatment.

研究实施时间:

Study execute time:

From 2021-08-01 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-08-01 00:00:00 To 2023-06-01 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

75

Group:

Experimental group

Sample size:

干预措施:

水疗加 tDCS

干预措施代码:

Intervention:

hydrotherapy plus tDCS

Intervention code:

组别:

对照组

样本量:

75

Group:

Control group

Sample size:

干预措施:

常规治疗

干预措施代码:

Intervention:

treatment as usual

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

黑龙江 

市(区县):

齐齐哈尔 

Country:

China 

Province:

Heilongjiang 

City:

Qiqihar 

单位(医院):

齐齐哈尔医学院附属第二医院 

单位级别:

三甲 

Institution
hospital:

the Second Affiliated Hospital of Qiqihar Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

粗大运动功能测量 88 (GMFM-88)

指标类型:

主要指标

Outcome:

Gross Motor Function Measure 88 (GMFM-88)

Type:

Primary indicator

测量时间点:

治疗开始和治疗 10 周后

测量方法:

Measure time point of outcome:

beginning of the treatment and after 10 weeks of therapy

Measure method:

指标中文名:

儿科平衡量表 (PBS)

指标类型:

主要指标

Outcome:

Pediatric Balance Scale (PBS)

Type:

Primary indicator

测量时间点:

治疗开始和治疗 10 周后

测量方法:

Measure time point of outcome:

beginning of the treatment and after 10 weeks of therapy

Measure method:

指标中文名:

儿科评估残疾清单 (PEDI)

指标类型:

次要指标

Outcome:

The Pediatric Evaluation Disability Inventory (PEDI)

Type:

Secondary indicator

测量时间点:

治疗开始和治疗 10 周后

测量方法:

Measure time point of outcome:

beginning of the treatment and after 10 weeks of therapy

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 4 years
最大 Max age 14 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机序列将通过随机数字表法和密封的不透明信封进行分配。 该过程将由不参与招募过程或研究开发的研究团队成员完成。 本研究将使用一系列编号的、密封的、不透明的信封。

Randomization Procedure (please state who generates the random number sequence and by what method):

The randomization sequence will be distributed by numerically sequenced and sealed opaque envelopes. This process will be completed out by a member of the research team who is not involved in the recruitment process or development of the study. A series of numbered, sealed, opaque envelopes will be used

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不适用

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

not applicable

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

我们将在治疗开始时和治疗10周后通过问卷对CP儿童进行评估。 记录所有研究参与者的结局指标和基本特征,例如年龄、性别、体重、身长、CP类型和结果。 数据将被收集并输入到计算机中的患者病历中,所有与患者相关的文件将被安全存储。 只有与研究相关的研究人员才能访问试验数据集。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

We will evaluate the CP children with subjective tests and objective questionnaires at the beginning of the treatment and after 10 weeks of therapy. Descriptive measures a.nd characteristics, such as age, gender, body weight, length, type of CP and the outcomes were recorded for all study participants. The data will be collected and entered into the patient’s medical record in a computer, and all patient related documents will be securely stored. Only the study-related investigators will be allowed to access to the trial dataset.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-06-28 03:53:21